基本信息
views: 38
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Kinney began his industrial career in the CNS group at Wyeth, where he invented unique NMDA antagonist perzinfotel (phase II clinical trials, stroke, pain). At Magainin Pharmaceuticals, he was an inventor of trodusquemine (phase II clinical trials, central control of obesity) and squalamine (phase II clinical trials, eye disease), two shark-derived natural products. He was the CMC leader on the IND project team, delivering drug substance to launch a Phase I clinical trial on time and on budget. The squalamine scale-up campaign required leading an internal process group, partnering with analytical chemistry on method development and stability studies, working with multiple domestic and international collaborators, and writing the CMC section of the IND. In 2000, he joined Johnson & Johnson, where he directed the AlphaV Beta3 Integrin Project, which generated multiple chemical series and 8 publications. Notably, JNJ-26076713 demonstrated utility in preventing proliferative neovascularization and vascular leakage in the eye after oral administration; and was proposed as a development candidate. He also made seminal discoveries with respect to self-assembling collagen-mimetic peptides that stimulate platelet aggregation.
As Founder of IteraMed Consulting, he has succeeded in advancing several projects which resulted in multiple patent filings and funding events. As part of the development activities, Dr. Kinney has led pharmaceutic efforts aimed at the optimum nanoformulation of a rapamycin conjugate for development at NanoPhagix. As a consultant to Kannalife Sciences, he discovered a new patented series of Cannabidiol-like molecules, including KLS-13019, with improved safety, bioavailability, potency and regulatory path. Most recently, Dr. Kinney co-founded Enterin Inc., which has been funded with VC funds to advance ENT-01 in Phase II clinical trials in Parkinson’s Disease. He is a contributing faculty member in the Master’s Program at the Geisinger Commonwealth School of Medicine.
Research Interests
Papers共 123 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Journal of Molecular Neuroscienceno. 2 (2024): 1-14
Journal of medicinal chemistryno. 14 (2023): 9519-9536
Tetrahedron Letters (2023): 154369-154369
Michael Camilleri,Thyagarajan Subramanian,Fernando Pagan,Stuart Isaacson,Ramon Gil,Robert A Hauser, Mary Feldman,Mark Goldstein,Rajeev Kumar,Daniel Truong, Nisha Chhabria,Benjamin L Walter,
Robert A. Hauser, Dean Sutherland,Juan A. Madrid,Maria Angeles Rol, Steven Frucht,Stuart Isaacson,Fernando Pagan, Brian N. Maddux,George Li,Winona Tse,Benjamin L. Walter,Rajeev Kumar,
Clinical Parkinsonism & Related Disorders (2019): 2-7
William A Kinney,Mark E McDonnell, Hua Marlon Zhong, Chaomin Liu, Lanyi Yang, Wei Ling, Tao Qian, Yu Chen, Zhijie Cai,Dean Petkanas,Douglas E Brenneman
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn